¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Blood Protein Disorders"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® blood ÇÑ±Û Ç÷¾×, ÇÇ
¼³¸í   
  ¼øÈ¯±â, Áï ½ÉÀå°ú Ç÷°ü ¾ÈÀ» ¼øÈ¯Çϴ À¯µ¿¼ºÀÇ Á¶Á÷À» ¸»ÇÑ´Ù. Ç÷¾×Àº Àüü Ã¼ÁßÀÇ ¾à 8%¸¦ Â÷ÁöÇϸç, ºñÁßÀº 1,056~1,059, Á¡µµ´Â ¾à 4.5, pH´Â 7.4ÀÌ´Ù. Ç÷¾×Àº ¾×ü¼ººÐÀΠÇ÷Àå°ú °Å±â¿¡ ¶°µ¹°í Àִ ¼¼Æ÷¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷ÀåÀº Àüü Ç÷¾×ÀÇ 55%¸¦ Â÷ÁöÇϸ砼öºÐ, ´Ü¹éÁú, Ç÷´ç, Áö¹æÁú, ¹«±â¿°·ù, Áú¼ÒÈ­ÇÕ¹°·Î ÀÌ·ç¾îÁø´Ù. ¼¼Æ÷¼ººÐÀº Àüü Ç÷¾×ÀÇ 45%¸¦ Â÷ÁöÇϸç ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖ¿ä ±â´ÉÀº Àü½Å Á¶Á÷À¸·Î »ê¼Ò¿Í ¿µ¾çºÐ °°Àº ÇÊ¿äÇÑ ¹°ÁúÀ» ¿î¹ÝÇϸ砺ÒÇÊ¿äÇÑ ¹°ÁúÀ» ¹è¼³±â°üÀ¸·Î ¿î¹ÝÇϴ ÀÏÀÌ´Ù. ±× ¹Û¿¡ »ýü¿¡ Çطο°ÁúÀ̳ª ¼¼±ÕÀ» Á¦°ÅÇϰí, ³»ºÎȯ°æÀÇ Çâ»ó¼ºÀ» À¯ÁöÇϸç, Ã¼¿ÂÀ¯Áö¿Í »ýü ¹æ¾î ±â´ÉÀ» ÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº ¿©·¯ °¡Áö ¼¼Æ÷ Ç÷±¸¿Í ±× ¼¼Æ÷¸¦ Æ÷ÇÔÇϴ ¸¼Àº ¾×üÀΠÇ÷Àå·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷±¸´Â ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ÀûÇ÷±¸´Â ºÓÀº »öÀ» ¶ì´Â ¼¼Æ÷·Î »ê¼Ò¸¦ ¸öÀÇ Á¶Á÷À¸·Î ¿î¹ÝÇϴ ¿ªÇÒÀ» ÇÑ´Ù. Ç÷¼ÒÆÇÀº Ç÷¾×ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù.
  
  ¹éÇ÷±¸´Â Àΰ£ÀÇ ¸é¿ª¿¡ °ü°èÇϴ ¼¼Æ÷À̸砱¸Ã¼ÀûÀ¸·Î ´ÙÀ½°ú °°Àº ¼¼Æ÷µéÀÌ ÀÖ´Ù.
  
  1.°ú¸³±¸(granulocyte): °ú¸³±¸¶õ ¹éÇ÷±¸ÀÇ 60%¸¦ Â÷ÁöÇϸç, ¼¼Æ÷¼Ó¿¡ Æ¯ÀÌÇÑ °ú¸³À» °¡Áö°í Àִ ¼¼Æ÷À̸ç, ´ÙÀ½°ú °°Àº 3°¡ÁöÀÇ ¼¼Æ÷°¡ À̰÷¿¡ Æ÷ÇÔÀÌ µÈ´Ù.
  
    -È£¿°±â±¸(basophil): ¿°±â¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ´Ù. ºÒ±ÔÄ¢ÇÑ ¸ð¾çÀÇ ¼¼Æ÷·Î Çª¸¥ »öÀ» ¶ì´Â °ú¸³ÀÌ ³Ê¹« ¸¹ÀÌ À־ ÇÙÀÌ Àß º¸ÀÌÁö ¾Ê´Â´Ù.
  
    -È£»ê±¸(eosinophil): »ê¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ°í, ´ë°³ ±â»ýÃæÀÇ °¨¿°À̳ª, ¾Ë·¯Áö¿¡¼­ ¸¹ÀÌ Áõ°¡ÇÑ´Ù. ´ë°³ 2°³ÀÇ ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº °ÍÀ¸·Î À̾îÁ® ÀÖ´Ù.
  
    -È£Áß±¸(neutrophil): »ê¼º¿°»ö¾àÀ̳ª ¿°±â¼º¿°»ö¾à¿¡ ÀÇÇÏ¿© ¸ðµÎ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö´Â ¼¼Æ÷·Î ´ë°³ 3°³ÀÇ ÇÙÀ» °¡Áø´Ù. ±×¸®°í ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº ±¸Á¶¹°ÀÌ À־ ÇÙÀ» ¼­·Î À̾îÁÖ°í ÀÖ´Ù.
  
  2.´ÜÇÙ±¸(monocyte): ´Ù°¢Çü¸ð¾çÀ» °¡Áø ¼¼Æ÷·Î °ú¸³À» °¡Áö°í ÀÖÁö ¾Ê´Ù. ¿Ü°è·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» Àâ¾Æ¸Ô´Â ¿ªÇÒ°ú ±×°Í¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇϴ ¿ªÇÒÀ» ÇÏ¿© ¸é¿ª¿¡ °ü°èÇÑ´Ù. À̰ÍÀÌ Ç÷¾× Áß¿¡ Á¸ÀçÇÏÁö ¾Ê°í Á¶Á÷¿¡ °íÁ¤µÇ¾î Àִ °æ¿ì¿¡ À̰ÍÀ» Å«Æ÷½Ä¼¼Æ÷¶ó°í ÇÑ´Ù.
  
  3.¸²ÇÁ±¸(lymphocyte): ÀÛÀº ¿øÇüÀÇ ¼¼Æ÷·Î ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù.
¿µ¹® blood gas ÇÑ±Û Ç÷¾×°¡½º, Ç÷¾×±âü
¼³¸í   
  Ç÷¾× ¼Ó¿¡ ¿ëÇØµÇ¾î Àִ »ê¼Ò, ÀÌ»êȭź¼Ò, Áú¼Ò µûÀ§ÀÇ ±âü. Ç÷¾×ÀÇ »ê¼º-¿°±â¼ºÀÇ Á¤µµ¸¦ ÃøÁ¤ÇÒ ¼ö ÀÖ´Ù.
¿µ¹® blood test ÇÑ±Û Ç÷¾×°Ë»ç
¼³¸í   
  Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇϴ °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é À̵頼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù.
¿µ¹® blood-brain barrier ÇÑ±Û Ç÷¾×³úÀ庮
¼³¸í   
  Ç÷¾×À¸·ÎºÎÅÍ ³ú·Î´Â ÁöÁú¿ëÇØ¼ºÀÌ ³ôÀº ¾à¹°¹Û¿¡ ÀÌÇàµÇÁö ¾Ê´Â´Ù. ¼ö¿ë¼ºÀÇ ¾à¹°À» ³ú·Î ÀÌÇàµÇÁö ¾Ê°Ô Çϰí Àִ °ÍÀÌ Ç÷¾×³úÀ庮À̸砳úÀÇ ¸ð¼¼Ç÷°ü ³»ÇǼ¼Æ÷, ¸ð¼¼Ç÷°ü ÁÖÀ§ÀÇ ¼¼Æ÷°¡ À庮ÀÌ µÇ°í ÀÖ´Ù. ¹°Áú±³È¯Àº ¼öµ¿È®»ê¿¡ ÀÇÇØ ÀÌ·ç¾îÁöÁö¸¸, ³úÀÇ »ý¸®Àû È°µ¿¿¡ ÇÊ¿äÇÑ ¹°ÁúÀº ÀÌ¿ÂÇüÀ̶󵵠´ãü¸¦ ÅëÇØ ÀÌÇàµÈ´Ù.
¿µ¹® blood volume ÇÑ±Û Ç÷¾×·®
¼³¸í   
  Ã¼³»¿¡ Á¸ÀçÇϴ Ç÷¾×ÀÇ ÃÑ·®À¸·Î¼­, º¸Åë ¸®ÅÍ ¶Ç´Â Ã¼Áß 1kg¿¡ ´ëÇÏ¿© ¸®Åͼö·Î Ç¥½ÃÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹éÁú, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • matrix protein
    ¹ÙÅÁÁú´Ü¹éÁú
  • membrane control protein
    ¸·Á¶Àý´Ü¹éÁú
  • olfactory binding protein
    Èİ¢°áÇմܹéÁú
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • principal outer membrane protein
    ÁÖ¹Ù±ù¸·´Ü¹éÁú, Áֿܸ·´Ü¹éÁú
  • prosthetic protein
    ¹èÇմܹéÁú
  • protein
    ´Ü¹éÁú
  • protein binding
    ´Ü¹éÁú°áÇÕ
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
  • protein granule
    ´Ü¹éÁú°ú¸³
  • protein kinase
    ´Ü¹éÁúŰ³ª¾ÆÁ¦
  • protein kinase C
    ´Ü¹éÁúŰ³ª¾ÆÁ¦C
  • protein layer
    ´Ü¹éÁúÃþ
  • protein p53
    ´Ü¹éÁúp53
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blood pressure fluctuation
    Ç÷¾Ðº¯µ¿, Ç÷¾Ð±âº¹
  • arterial blood gas
    µ¿¸ÆÇ÷°¡½º
  • blood grouping
    Ç÷¾×Çü°Ë»ç
  • blood gas
    Ç÷¾×°¡½º
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood urea nitrogen
    Ç÷¾×¿ä¼ÒÁú¼Ò
  • blood pressure
    Ç÷¾Ð
  • blood product
    Ç÷¾×Á¦Á¦
  • portal blood pressure
    ¹®¸Æ¾Ð
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • blood sugar
    Ç÷´ç
  • blood supply
    Ç÷¾×°ø±Þ
  • blood group system
    Ç÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • matrix protein
    ¹ÙÅÁÁú´Ü¹é
  • membrane control protein
    ¸·Á¶Àý´Ü¹é
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹é, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • olfactory binding protein
    Èİ¢°áÇմܹé
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • protein
    ´Ü¹é, ´Ü¹éÁú
  • principal outer membrane protein
    Áֿܸ·´Ü¹éÁú
  • prosthetic protein
    ¹èÇմܹé
  • protein quotient
    ´Ü¹éÁö¼ö
  • protein score
    ´Ü¹é°¡
  • protein sensitization
    ´Ü¹é¹Î°¨
  • reserve protein
    ÀúÀå´Ü¹éÁú
  • specific protein
    ƯÀ̴ܹéÁú
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
  • stress protein
    ½ºÆ®·¹½º´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • MBP=£¾mean blood pressure
    Áß°£Ç÷¾Ð ¡ìÀÏÀÎÀÇ¡í, Æò±ÕÇ÷¾Ð.
  • Manson blood fluke
    ¸¸¼ÕÇ÷ÈíÃæ
  • OMNISTIK blood gas syringe
    ¿È´Ï½ºÆ½Ç÷¾×°¡½ºÁÖ»ç±â
  • P blood group system
    PÇ÷¾×Çü±º
  • RBC=£¾red blood cell
    ÀûÇ÷±¸.
  • Rh blood group
    RhÇ÷¾×Çü.
  • Rh blood group
    Rh Ç÷¾×Çü
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • Schaedler blood agar
    ¼¨µé·¯Ç÷¾×ÇÑõ
  • accessory blood vessel
    ºÎÇ÷°ü, Á¾¼ÓÇ÷°ü
  • arterial blood
    µ¿¸ÆÇ÷.
  • arterial blood gas
    µ¿¸ÆÇ÷°¡½º
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
  • arterial blood pressure
    µ¿¸ÆÇ÷¾Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • nutritional disorders
    ¿µ¾çÀÌ»ó<Àå¾Ö>.
  • olfactory disorders
    Èİ¢Àå¾Ö
  • organic voice disorders
    ±âÁú(Àû) À½¼ºÀå¾Ö
  • platelet function disorders
    Ç÷¼ÒÆÇ±â´ÉÀÌ»óÁúȯ
  • postpartum disorders
    »êÈÄ Àå¾Ö(º´)
  • psychogenic voice disorders
    ½ÉÀÎ(¼º) À½¼ºÀå¾Ö
  • sensation disorders
    Áö°¢<°¨°¢>Àå¾Ö .
  • sex limited disorders
    ÇѼºÀå¾Ö(ùÚàõî¡äô)
  • sex linked disorders
    ¹Ý¼ºÀå¾Ö(Úáàõî¡äô)
  • sexual and gender identity disorders
    ¼º ¹× Á¤½Å¼ºÀû ÁÖü¼ºÀå¾Ö(º´)
  • sleep-related disorders
    ¼ö¸é°ü·ÃÀå¾Ö(º´)
  • social stress, mood disorders and
    »çȸÀû ½ºÆ®·¹½º
  • somatic disorders
    ½ÅüÀå¾Ö(ãóô÷î¡äô).
  • specific developmental disorders of scholastic skill
    ƯÁ¤ Çо÷±â¼ú ¹ß´ÞÀå¾Ö
  • specific developmental disorders of speech and languages
    ƯÁ¤ ¸»Çϱâ¿Í ¾ð¾îÀÇ ¹ß´ÞÀå¾Ö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • binding protein
    °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • binding protein transport system
    °áÇÕ ´Ü¹éÁú ¼ö¼Û(Ì¿ùêÓ±ÛÜòõâÃáê) ½Ã½ºÅÛ
  • biotin carboxyl carrier protein
    ¹ÙÀÌ¿Àƾ Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • blue copper protein
    ûµ¿ ´Ü¹éÁú(ôìÔÞÓ±ÛÜòõ)
  • blue protein
    û´Ü¹éÁú(ôìÓ±ÛÜòõ)
  • B protein
    B ´Ü¹éÁú(Ó±ÛÜòõ)
  • Ca2+-dependent regulatory protein
    Ca2+-ÀÇÁ¸(ëîðí) Á¶Àý´Ü¹éÁú(ðàï½Ó±ÛÜòõ)
  • calcium-dependent regulatory protein
    Ä®½·ÀÇÁ¸ Á¶Àý´Ü¹éÁú(ëîðíðàï½Ó±ÛÜòõ)
  • cAMP-dependent protein kinase
    cAMPÀÇÁ¸(ëîðí) ´Ü¹éÁú(Ó±ÛÜòõ) Ȱ¼ºÈ­È¿¼Ò(üÀàõûùý£áÈ)
  • carboxyl carrier protein
    Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • carrier protein
    ¿î¹Ýü´Ü¹éÁú(ê¡Úæô÷Ó±ÛÜòõ)
  • catabolite activator protein
    īŸº¼¶óÀÌÆ® Ȱ¼ºÈ­ ´Ü¹éÁú(üÀàõûùÓ±ÛÜòõ)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cellular retinol-binding protein
    ¼¼Æ÷(á¬øà) ·¹Æ¼³î°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • channel protein
    ä³Î ´Ü¹éÁú(Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • liver blood flow
    °£ÀåÇ÷¾×À¯Åë, °£Ç÷·ù
  • maximal blood pressure
    ÃÖ´ëÇ÷¾Ð, ÃÖ°íÇ÷¾Ð
  • occult blood
    ÀáÇ÷
  • portal blood pressure
    ¹®¸Æ¾Ð
  • red blood cell
    ÀûÇ÷±¸
  • systemic blood pressure
    üÇ÷¾Ð
  • white blood cell
    ¹éÇ÷±¸
  • whole blood
    ÀüÇ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
BlT bleeding time; blood test; blood type, blood typing
CBL circulating blood lymphocytes; chronic blood loss; cord blood leukocytes
DRBC denaturated red blood cell; dog red blood cell; donkey red blood cell
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IDD Iodine Deficiency Disorders
LBD Low-back disorders
NINDS National Institute of Neurological Disorders and Stroke
NMD Neuronal migration disorders
PBD Peroxisome biogenesis disorders
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • serum amyloid protein A
    Ç÷û ¾Æ¹Ð·ÎÀ̵å ÇÁ·Îƾ A
  • serum protein
    Ç÷Àå ´Ü¹é
  • serum protein meter
    Ç÷û ´Ü¹é°è
    Ç÷û ´Ü¹é Á¤·®¿ëÀÇ ¼ÒÇü ±¼Àý°è.
  • silver protein mild
    ¾à·Â ÇÁ·ÎÅ×ÀÎ Àº
    Àº 19¡­23%¸¦ ÇÔÀ¯Çϰí, ´Ü¹éÁúÀÇ Á¸Àç ¶Ç´Â ´Ü¹é°úÀÇ °áÇÕ¿¡ ÀÇÇØ¼­ ÄÝ·ÎÀ̵åÈ­ÇÑ Á¦Á¦. ¾Ï°¥»ö ¶Ç´Â °ÅÀÇ Èæ»öÀÇ ºñ´Ã ¶Ç´Â °ú¸³À¸·Î¼­ Á÷Àå, ´«, Áú, ¿äµµ, ±Í, ÄÚ, ¹× ÀεΠµîÀÇ ¿©·¯ °¡Áö °¨¿°Áõ¿¡ ±¹¼Ò¿ë Ç×°¨¿°Á¦·Î »ç¿ëÇÑ´Ù.
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • arterial blood gas
    µ¿¸ÆÇ÷ °¡½º ºÐ¾Ð
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • artificial blood vessel
    Àΰø Ç÷°ü
  • autoimmune blood dyscrasia
    ÀÚ°¡ ¸é¿ª¼º Ç÷¾× ÀÌ»ó
  • autologous blood recovery system
    ÀÚ°¡ Ç÷¾× ȸº¹ ÀåÄ¡
  • automated noninvasive blood pressure device
    ºñħ½ÀÀû ÀÚµ¿ Ç÷¾Ð±â
  • basal blood pressure
    ±âÀú Ç÷¾Ð
  • black blood imaging
    ÈæÇ÷·ù ¿µ»ó
  • blood
    ÇÇ, Ç÷¾×
    1. ¸Æ°ü°è¸¦ È帣°í ÀÖ´Â ¾×ü·Î ¼¼Æ÷ ¼ººÐÀÎ Ç÷±¸¿Í Ç÷ûÀ¸·Î ±¸¼ºµÈ´Ù. ½ÉÀå ¹× Ç÷°ü Áï ¼øÈ¯°è¸¦ ä¿ì°í ÀÖ´Â ¾×üÀÌ´Ù. 2. ÇÇ, ½ÉÀå, µ¿¸Æ, ¸ð¼¼Ç÷°ü ¹× Á¤¸Æ³»¸¦ ¼øÈ¯Çϸ鼭 ½Åü³» ¼¼Æ÷¿¡ ¿µ¾çºÐ°ú »ê¼Ò¸¦ ¿î¹ÝÇÏ´Â ¾×üÀ̸ç, ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇ µîÀ» Æ÷ÇÔÇÑ À¯Çü ¼ººÐ°ú Ç÷ÀåÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. 3. ²öÀû²öÀûÇÑ ¾×ü·Î¼­, ÀûÇ÷±¸ÀÇ Ç÷»ö¼Ò ?¹®¿¡ ¼±È«»öÀ» ¶è´Ù. 4. Ç÷°ü ¼ÓÀ» È帣°í ÀÖ´Â ¾×»óÀÇ Á¶Á÷. ¼±¸íÇÑ Àû»öÀ» ¶ì°í ÀÖ°í ºÒÅõ¸íÇÏ¸ç ±ÕÀÏÇÏ°Ô º¸ÀδÙ. ±×·¯³ª Ç÷¾×ÀÇ ÀÛÀº ¹æ¿ïÀ» À¯¸®ÆÇ¿¡ ¾ã°Ô Æì°í Çö¹Ì°æÀ¸·Î º¸¸é Åõ¸íÇÑ ¾×ü ¼Ó¿¡ Ç÷±¸°¡ ºÎÀ¯Çϰí ÀÖ¾î ±ÕÀÏÇÏÁö ¾ÊÀ½À» ¾Ë ¼ö ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖµÈ ¿ªÇÒÀº °¢Á¾ ¹°ÁúÀÇ ¿î¹ÝÀ̸ç, Æó¿¡¼­ ¼·ÃëÇÑ »ê¼Ò³ª ¼ÒÈ­°ü¿¡¼­ Èí¼öÇÑ ¿µ¾ç¼Ò µîÀ» Àü½ÅÀÇ ¸ðµç ¼¼Æ÷·Î º¸³»°í ¹Ý´ë·Î ¼¼Æ÷¿¡¼­ ¸¸µé¾îÁø ź»ê°¡½º³ª ³ëÆó¹°À» ¿î¹ÝÇØ¼­ Æó, ½ÅÀå, ÇǺΠµîÀ» ÅëÇØ¼­ ¸ö¹ÛÀ¸·Î ¹è¼³ÇÑ´Ù. ¶Ç °ñ°Ý±ÙÀ̳ª °£°ú °°ÀÌ ¿­ »ý»êÀÌ ¿Õ¼ºÇÑ °÷À¸·ÎºÎÅÍ ´Ù¸¥ ºÎºÐÀ¸·Î ¿­À» ¿Å°Ü¼­ ü¿­ÀÇ ºÐÆ÷¸¦ ±ÕµîÇÏ°Ô Çϰí, ÇǺο¡¼­ ¹æ¿­ÇÏ¿© ü¿ÂÀ» ÀÏÁ¤ÇÏ°Ô À¯Áö½ÃŰ´Â µ¥µµ °ü¿©ÇÑ´Ù. Ç÷¾×·®Àº üÁßÀÇ ¾à 8 %, ºñÁßÀº 1.06À̹ǷΠüÁßÀÌ 60 kgÀÎ ¶§ ¾à 4.5§¤°¡ µÈ´Ù. Ç÷¾×·®Àº °ÅÀÇ ÀÏÁ¤Çؼ­ ¾×ü¸¦ ¼·ÃëÇßÀ» ¶§³ª ÀûÀº ¾çÀÇ ÃâÇ÷ÀÌ ÀÖÀ» ¶§µµ Ç÷°ü ¼ÓÀÇ ¼øÈ¯ Ç÷¾×·®À» ÀÚÀ²ÀûÀ¸·Î Á¶ÀýÇÏ¿© Àüü Ç÷¾×·®Àº º¯ÇÏÁö ¾Ê´Â´Ù. ÇÑÆí, ´ë·®ÀÇ ¹°À» ¸¶¼ÌÀ» ¶§ ¼öºÐÀº °ð Ç÷¾×¿¡¼­ Á¶Á÷À¸·Î ³ª°¡°Å³ª ½ÅÀåÀ¸·ÎºÎÅÍ ¹è¼³µÈ´Ù. Ç÷¾×ÀÇ Á¡Á¶µµ´Â ¹°ÀÇ ¾à 5¹èÀ̰í, ÁÖ·Î Ç÷±¸ ¼ö¿¡ µû¶ó º¯ÇÑ´Ù. ºóÇ÷ÀÏ ¶§Ã³·³ ÀûÇ÷±¸°¡ °¨¼ÒÇϸé Á¡Á¶µµ°¡ ³·¾ÆÁ®¼­ Ç÷¾×ÀÌ Ç÷°ü ³»¸¦ È带 ¶§ ÀúÇ×ÀÌ °¨¼ÒµÇ¹Ç·Î Ç÷¾ÐÀÌ ¶³¾îÁø´Ù. µû¶ó¼­ Ç÷¾×ÀÇ Á¡Á¶µµ°¡ Ç÷¾ÐÀ» À¯ÁöÇÏ´Â µ¥¿¡ Áß¿äÇÑ ±¸½ÇÀ» Çϰí ÀÖÀ½À» ¾Ë ¼ö ÀÖ´Ù. Ç÷¾×ÀÇ »ïÅõ¾ÐÀº 6.7±â¾ÐÀ¸·Î 0.9 %ÀÇ ½Ä¿°¼ö¿Í °°´Ù. ¸¸¾à Ç÷¾×º¸´Ù ³·Àº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö¿¡ Ç÷¾×À» ³ÖÀ¸¸é Ç÷±¸ ¼Ó¿¡ ¼öºÐÀÌ »¡·Á µé¾î°¡ ºÎÇ®¾î ¸¶Ä§³»´Â ÆÄ±«µÈ´Ù. À̰ÍÀ» ¿ëÇ÷À̶ó°í ÇÑ´Ù. ¶Ç ¹Ý´ë·Î Ç÷¾×º¸´Ù ³ôÀº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö ¾È¿¡¼­´Â Ç÷±¸ ¼ÓÀÇ ¼öºÐÀÌ ¹ÛÀ¸·Î ³ª¿Í Ç÷±¸´Â ¿À±×¶óµé°í ¸¸´Ù. ±×¸®°í Ç÷¾×°ú °°Àº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö¸¦ »ý¸®Àû ½Ä¿°¼ö¶ó ÇÑ´Ù. Ç÷¾×ÀÇ
  • blood agar
    Ç÷¾× ÇÑõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
phobic disorders Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognises the fear as excessive or unreasonable.
(12 Dec 1998)
civil disorders Deliberate and planned acts of unlawful behaviour engaged in by aggrieved segments of the population in seeking social change.
(12 Dec 1998)
phosphorus metabolism disorders Disorders in the processing of phosphorus in the body: its absorption, transport, storage, and utilization.
(12 Dec 1998)
photosensitivity disorders Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy.
(12 Dec 1998)
mood disorders Those disorders that have a disturbance in mood as their predominant feature.
(12 Dec 1998)
combat disorders Neurotic reactions to unusual, severe, or overwhelming military stress.
(12 Dec 1998)
communication disorders Disorders characterised by the individual's inability to comprehend or share ideas or feelings because of impairment of language, speech, or hearing.
(12 Dec 1998)
motor skills disorders Marked impairments in the development of motor coordination such that the impairment interferes with activities of daily living.
(12 Dec 1998)
platelet function disorders <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(31 Dec 1997)
multifactorial or multigenic disorders Genetic disorders resulting from the combined action of alleles of more than one gene (e.g., heart disease, diabetes, and some cancers). Although such disorders are inherited, they depend on the simultaneous presence of several alleles, thus the hereditary patterns are usually more complex than those of single- gene disorders.
Compare single-gene disorders.
(05 Mar 2000)
consciousness disorders Organic mental disorders in which there is marked impairment of awareness.
(12 Dec 1998)
polygenic disorders Genetic disorders resulting from the combined action of alleles of more than one gene (e.g., heart disease, diabetes, and some cancers). Although such disorders are inherited, they depend on the simultaneous presence of several alleles, thus the hereditary patterns are usually more complex than those of single- gene disorders.
Compare single-gene disorders.
(05 Mar 2000)
myeloproliferative disorders A group of disease states which primarily involve the bone marrow and the production blood cells.
Examples include polycythaemia vera, leukaemia, myelofibrosis and primary thrombocytopenia.
(27 Sep 1997)
craniomandibular disorders Diseases or disorders of the muscles of the head and neck, with special reference to the masticatory muscles. The most notable examples are temporomandibular joint disorders and temporomandibular joint dysfunction syndrome.
(12 Dec 1998)
cumulative trauma disorders Harmful and painful condition caused by overuse or overexertion of some part of the musculoskeletal system, often resulting from work-related physical activities. It is characterised by inflammation, pain, or dysfunction of the involved joints, bones, ligaments, and nerves.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • full blood
    ¼øÁ¾ÀÇ »ç¶÷
  • half blood
    À̺¹,¹è(´Ù¸¥)°ü°è
  • half blood
    ¹è´Ù¸¥;¾¾´Ù¸¥
  • half blood
    (ÇüÁ¦,ÀڸŰ¡)¹è(¾¾)°¡ ´Ù¸§;¹è(¾¾) ´Ù¸¥ ÇüÁ¦(ÀÚ¸Å)
  • heart's blood
    ½ÉÀå³»ÀÇ Ç÷¾×;½ÉÇ÷;»ý¸í;Áø½É;»ý¸í·Â;¼ÒÁßÇÑ °Í
  • high blood pressure
    °íÇ÷¾Ð
  • ill blood
    ¾ÇÀÇ;¾Ó½É;Àû´ë½É;¿øÇÑ
  • new blood
    (»õ·Î¿î Ȱ·Â(»ç»ó)ÀÇ ¿øÃµÀ¸·Î¼­ÀÇ)ÀþÀºÀ̵é;½ÅÀεé
  • red blood cell(corpuscle)
    ÀûÇ÷±¸
  • young blood
    ûÃáÀÇ Ç÷±â;ÀþÀºÀ̵é
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á